CNR1 and Huntington disease: Therapeutic studies of cannabinoid-based agents in HD animal models suggest that CB1 and endo vanilloid receptor agonists [174,175] and AEA reuptake inhibitors [176] can prevent hyperkinesia in the early phases of HD.